168 related articles for article (PubMed ID: 18364570)
1. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice.
Guo K; Tang JP; Tan CP; Wang H; Zeng Q
Cancer Biol Ther; 2008 May; 7(5):750-7. PubMed ID: 18364570
[TBL] [Abstract][Full Text] [Related]
2. Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases.
Li J; Guo K; Koh VW; Tang JP; Gan BQ; Shi H; Li HX; Zeng Q
Clin Cancer Res; 2005 Mar; 11(6):2195-204. PubMed ID: 15788667
[TBL] [Abstract][Full Text] [Related]
3. PRL phosphatases as potential molecular targets in cancer.
Stephens BJ; Han H; Gokhale V; Von Hoff DD
Mol Cancer Ther; 2005 Nov; 4(11):1653-61. PubMed ID: 16275986
[TBL] [Abstract][Full Text] [Related]
4. Phosphatase of regenerating liver: a novel target for cancer therapy.
Campbell AM; Zhang ZY
Expert Opin Ther Targets; 2014 May; 18(5):555-69. PubMed ID: 24579927
[TBL] [Abstract][Full Text] [Related]
5. Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis.
Wang Y; Li ZF; He J; Li YL; Zhu GB; Zhang LH; Li YL
Int J Colorectal Dis; 2007 Oct; 22(10):1179-84. PubMed ID: 17440740
[TBL] [Abstract][Full Text] [Related]
6. Targeting PRL phosphatases in hematological malignancies.
Xiao S; Chen H; Bai Y; Zhang ZY; Liu Y
Expert Opin Ther Targets; 2024 Apr; 28(4):259-271. PubMed ID: 38653737
[TBL] [Abstract][Full Text] [Related]
7. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome.
Zeng Q; Si X; Horstmann H; Xu Y; Hong W; Pallen CJ
J Biol Chem; 2000 Jul; 275(28):21444-52. PubMed ID: 10747914
[TBL] [Abstract][Full Text] [Related]
8. Targeting phosphatases of regenerating liver (PRLs) in cancer.
Wei M; Korotkov KV; Blackburn JS
Pharmacol Ther; 2018 Oct; 190():128-138. PubMed ID: 29859177
[TBL] [Abstract][Full Text] [Related]
9. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility.
Fiordalisi JJ; Keller PJ; Cox AD
Cancer Res; 2006 Mar; 66(6):3153-61. PubMed ID: 16540666
[TBL] [Abstract][Full Text] [Related]
10. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo.
Guo K; Li J; Wang H; Osato M; Tang JP; Quah SY; Gan BQ; Zeng Q
Cancer Res; 2006 Oct; 66(19):9625-35. PubMed ID: 17018620
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of the PRL phosphatases.
Rios P; Li X; Köhn M
FEBS J; 2013 Jan; 280(2):505-24. PubMed ID: 22413991
[TBL] [Abstract][Full Text] [Related]
12. Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels.
Guo K; Li J; Tang JP; Koh V; Gan BQ; Zeng Q
Cancer Biol Ther; 2004 Oct; 3(10):945-51. PubMed ID: 15326366
[TBL] [Abstract][Full Text] [Related]
13. Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo.
Song R; Qian F; Li YP; Sheng X; Cao SX; Xu Q
PLoS One; 2009; 4(2):e4450. PubMed ID: 19214221
[TBL] [Abstract][Full Text] [Related]
14. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells.
Wang L; Shen Y; Song R; Sun Y; Xu J; Xu Q
Mol Pharmacol; 2009 Dec; 76(6):1238-45. PubMed ID: 19779032
[TBL] [Abstract][Full Text] [Related]
15. PRL-3 expression in metastatic cancers.
Bardelli A; Saha S; Sager JA; Romans KE; Xin B; Markowitz SD; Lengauer C; Velculescu VE; Kinzler KW; Vogelstein B
Clin Cancer Res; 2003 Nov; 9(15):5607-15. PubMed ID: 14654542
[TBL] [Abstract][Full Text] [Related]
16. Phosphatase of regenerating liver-1 promotes cell migration and invasion and regulates filamentous actin dynamics.
Nakashima M; Lazo JS
J Pharmacol Exp Ther; 2010 Aug; 334(2):627-33. PubMed ID: 20484558
[TBL] [Abstract][Full Text] [Related]
17. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.
Zeng Q; Dong JM; Guo K; Li J; Tan HX; Koh V; Pallen CJ; Manser E; Hong W
Cancer Res; 2003 Jun; 63(11):2716-22. PubMed ID: 12782572
[TBL] [Abstract][Full Text] [Related]
18. 1H, 15N, 13C resonance assignments of the reduced and active form of human Protein Tyrosine Phosphatase, PRL-1.
Skinner AL; Laurence JS
Biomol NMR Assign; 2009 Jun; 3(1):61-5. PubMed ID: 19636948
[TBL] [Abstract][Full Text] [Related]
19. PRL-3 phosphatase is implicated in ovarian cancer growth.
Polato F; Codegoni A; Fruscio R; Perego P; Mangioni C; Saha S; Bardelli A; Broggini M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6835-9. PubMed ID: 16203771
[TBL] [Abstract][Full Text] [Related]
20. Novel Anticancer Agents Based on Targeting the Trimer Interface of the PRL Phosphatase.
Bai Y; Yu ZH; Liu S; Zhang L; Zhang RY; Zeng LF; Zhang S; Zhang ZY
Cancer Res; 2016 Aug; 76(16):4805-15. PubMed ID: 27325652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
